These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 28640667)
1. Restricting retrotransposons: ADAR1 is another guardian of the human genome. Orecchini E; Frassinelli L; Michienzi A RNA Biol; 2017 Nov; 14(11):1485-1491. PubMed ID: 28640667 [TBL] [Abstract][Full Text] [Related]
5. Effects of Aicardi-Goutières syndrome mutations predicted from ADAR-RNA structures. Fisher AJ; Beal PA RNA Biol; 2017 Feb; 14(2):164-170. PubMed ID: 27937139 [TBL] [Abstract][Full Text] [Related]
6. Adenosine-to-inosine RNA editing in the immune system: friend or foe? Nakahama T; Kawahara Y Cell Mol Life Sci; 2020 Aug; 77(15):2931-2948. PubMed ID: 31996954 [TBL] [Abstract][Full Text] [Related]
7. Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown. Chung H; Calis JJA; Wu X; Sun T; Yu Y; Sarbanes SL; Dao Thi VL; Shilvock AR; Hoffmann HH; Rosenberg BR; Rice CM Cell; 2018 Feb; 172(4):811-824.e14. PubMed ID: 29395325 [TBL] [Abstract][Full Text] [Related]
8. Aicardi-Goutières syndrome-associated mutation at ADAR1 gene locus activates innate immune response in mouse brain. Guo X; Wiley CA; Steinman RA; Sheng Y; Ji B; Wang J; Zhang L; Wang T; Zenatai M; Billiar TR; Wang Q J Neuroinflammation; 2021 Jul; 18(1):169. PubMed ID: 34332594 [TBL] [Abstract][Full Text] [Related]
9. The role of RNA editing enzyme ADAR1 in human disease. Song B; Shiromoto Y; Minakuchi M; Nishikura K Wiley Interdiscip Rev RNA; 2022 Jan; 13(1):e1665. PubMed ID: 34105255 [TBL] [Abstract][Full Text] [Related]
10. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Rice GI; Kasher PR; Forte GM; Mannion NM; Greenwood SM; Szynkiewicz M; Dickerson JE; Bhaskar SS; Zampini M; Briggs TA; Jenkinson EM; Bacino CA; Battini R; Bertini E; Brogan PA; Brueton LA; Carpanelli M; De Laet C; de Lonlay P; del Toro M; Desguerre I; Fazzi E; Garcia-Cazorla A; Heiberg A; Kawaguchi M; Kumar R; Lin JP; Lourenco CM; Male AM; Marques W; Mignot C; Olivieri I; Orcesi S; Prabhakar P; Rasmussen M; Robinson RA; Rozenberg F; Schmidt JL; Steindl K; Tan TY; van der Merwe WG; Vanderver A; Vassallo G; Wakeling EL; Wassmer E; Whittaker E; Livingston JH; Lebon P; Suzuki T; McLaughlin PJ; Keegan LP; O'Connell MA; Lovell SC; Crow YJ Nat Genet; 2012 Nov; 44(11):1243-8. PubMed ID: 23001123 [TBL] [Abstract][Full Text] [Related]
11. An I for an A: Dynamic Regulation of Adenosine Deamination-Mediated RNA Editing. Vesely C; Jantsch MF Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356042 [TBL] [Abstract][Full Text] [Related]
12. Mutations in the adenosine deaminase ADAR1 that prevent endogenous Z-RNA binding induce Aicardi-Goutières-syndrome-like encephalopathy. Nakahama T; Kato Y; Shibuya T; Inoue M; Kim JI; Vongpipatana T; Todo H; Xing Y; Kawahara Y Immunity; 2021 Sep; 54(9):1976-1988.e7. PubMed ID: 34525338 [TBL] [Abstract][Full Text] [Related]
13. RNA-editing enzymes ADAR1 and ADAR2 coordinately regulate the editing and expression of Ctn RNA. Anantharaman A; Gholamalamdari O; Khan A; Yoon JH; Jantsch MF; Hartner JC; Gorospe M; Prasanth SG; Prasanth KV FEBS Lett; 2017 Sep; 591(18):2890-2904. PubMed ID: 28833069 [TBL] [Abstract][Full Text] [Related]
14. Sensitive ADAR editing reporter in cancer cells enables high-throughput screening of small molecule libraries. Fritzell K; Xu LD; Otrocka M; Andréasson C; Öhman M Nucleic Acids Res; 2019 Feb; 47(4):e22. PubMed ID: 30590609 [TBL] [Abstract][Full Text] [Related]
15. ADAR1 prevents autoinflammation by suppressing spontaneous ZBP1 activation. de Reuver R; Verdonck S; Dierick E; Nemegeer J; Hessmann E; Ahmad S; Jans M; Blancke G; Van Nieuwerburgh F; Botzki A; Vereecke L; van Loo G; Declercq W; Hur S; Vandenabeele P; Maelfait J Nature; 2022 Jul; 607(7920):784-789. PubMed ID: 35859175 [TBL] [Abstract][Full Text] [Related]
16. Adenosine-to-inosine editing of endogenous Z-form RNA by the deaminase ADAR1 prevents spontaneous MAVS-dependent type I interferon responses. Tang Q; Rigby RE; Young GR; Hvidt AK; Davis T; Tan TK; Bridgeman A; Townsend AR; Kassiotis G; Rehwinkel J Immunity; 2021 Sep; 54(9):1961-1975.e5. PubMed ID: 34525337 [TBL] [Abstract][Full Text] [Related]
17. Processing of Shiromoto Y; Sakurai M; Qu H; Kossenkov AV; Nishikura K RNA; 2020 Dec; 26(12):1801-1814. PubMed ID: 32817447 [TBL] [Abstract][Full Text] [Related]
18. ADAR1 interaction with Z-RNA promotes editing of endogenous double-stranded RNA and prevents MDA5-dependent immune activation. de Reuver R; Dierick E; Wiernicki B; Staes K; Seys L; De Meester E; Muyldermans T; Botzki A; Lambrecht BN; Van Nieuwerburgh F; Vandenabeele P; Maelfait J Cell Rep; 2021 Aug; 36(6):109500. PubMed ID: 34380029 [TBL] [Abstract][Full Text] [Related]
19. Editor meets silencer: crosstalk between RNA editing and RNA interference. Nishikura K Nat Rev Mol Cell Biol; 2006 Dec; 7(12):919-31. PubMed ID: 17139332 [TBL] [Abstract][Full Text] [Related]
20. Adenosine-to-inosine Alu RNA editing controls the stability of the pro-inflammatory long noncoding RNA NEAT1 in atherosclerotic cardiovascular disease. Vlachogiannis NI; Sachse M; Georgiopoulos G; Zormpas E; Bampatsias D; Delialis D; Bonini F; Galyfos G; Sigala F; Stamatelopoulos K; Gatsiou A; Stellos K J Mol Cell Cardiol; 2021 Nov; 160():111-120. PubMed ID: 34302813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]